Navigation Links
AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency
Date:5/15/2008

AARP commends Governor Paterson's leadership in proposing prescription drug marketing reform and transparency

ALBANY, N.Y., May 15 /PRNewswire-USNewswire/ -- AARP strongly believes New York has a paramount interest in passing the Governor's prescription marketing reform proposals which address the undue influence that pharmaceutical companies have over prescribing decisions that affect not only consumers' pocket books but the treatment they receive.

The reforms include banning gifts of over $50 (excluding free samples) to doctors and requiring speakers at continuing medical education programs for health professionals to disclose any financial relationships they might have with a drug company.

AARP strongly supports provisions in the proposed legislation to make the business transactions of pharmaceutical benefit managers (PBMs) more transparent in order to drive down the cost of prescription drugs.

We strongly encourage the New York State Legislature to pass this legislation that would help so many New Yorkers before the end of the legislative session. The pharmaceutical industry should not dictate prescription drug policy in our State. The Legislature must reject the opposition from the drug industry and do the right thing for their constituents.

The Governor's bill will increase a New Yorker's ability to access affordable prescription drugs and improve the quality of their healthcare. In addition, this legislation would help all taxpayers who fund public prescription drug programs, such as Medicaid and EPIC.

According to a January 2006 article in the Journal of the American Medical Association (JAMA), titled "Health Industry Practices That Create Conflicts of Interest," approximately 90% of the $21 billion pharmaceutical industry marketing budget continues to be directed at physicians.

When a drug company sales representative walks into a doctor's office armed with gifts and promotes a drug company's newest, most expensive drugs, New Yorkers - whether as patients or taxpayers - may not always obtain the most beneficial and cost-effective drug available.

For several years, AARP has been tracking the price of prescription drugs. AARP's Rx Watchdog reports have revealed startling trends over the past six years. Brand name prescription drug costs are steadily rising at close to double and even triple the rate of inflation.

AARP firmly believes that evidence-based research should be the guide to prescribing the most effective prescription drugs, not gifts from manufacturers to physicians. Drugs should be prescribed based on their effectiveness in treating a medical condition - not because they are new and in many cases more expensive.


'/>"/>
SOURCE AARP New York
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology: